Approaches and Tools to Consider to Maximise Success on the Therapeutic Protein Journey from Research Product to Clinic
In collaboration with..
Attendance at this event is complimentary.
This event is primarily focused on early stage life science innovators, biotechs, companies in bioincubators and translational research groups with an interest in protein expression and approaches/tools to successfully scale. Please note, all registrations are subject to the approval of the sponsor and registration cancelled if they are not considered to meet the above criteria. You will be informed if your registration has been cancelled within 2 working days of registering online for the event.
Email Alicia for further information.
One Nucleus is collaborating with Lonza to bring you a complimentary symposium on Thursday 2 May at The Babraham Research Campus, Cambridge to gain insight from experts in the different approaches and techniques to successfully progress therapeutic proteins from discovery to the clinic. Enjoy updates on enhancements to new and established technologies enabling translational research.
Pre-book 1-on-1 sessions with Lonza specialists at the Drop-in-Clinics that will follow the talks. While you wait for your session, enjoy a parallel track featuring presentations from local companies and leading academics.
Our networking lunch offers the opportunity to meet with other esteemed guests, speakers and Lonza commercial specialists.
Agenda
08.30 – 09.00
Delegate Registration, Networking over Tea and Coffee
09.00 – 09.15
Welcome
- Tony Jones, CEO, One Nucleus
- Sarah Holland, Global Head of Licensing, Lonza
09.15 – 09:50
Early developability assessment tools – successful de-risking strategies to support progression of biologics from discovery to development
- Yvette Stallwood, Head of Applied Protein Services, Lonza
09:50 – 10.35
Overview and recent enhancements to the Lonza GS Xceed® Toolbox, including the introduction of GS piggyBac™
- Alison Porter, Head of Expression System Sciences, Lonza
10.35 – 11.15
Recent enhancements to Lonza’s microbial expression technologies – featuring Pichia pastoris 2.0
- Nikolay Krumov, Senior Project Leader Upstream Development Microbial, Lonza AG Switzerland
11.15 – 11.30
Coffee Break
11.30 – 13.00
Drop-in-Clinic Sessions Commence
- Meet Lonza specialists at pre-booked 1-on-1 sessions
- Parallel session featuring presentations from industry
Speakers include:
- A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression - Dr Richard Sainson, Senior Director Translational Medicine, Kymab
- Developability studies to ensure successsful development of high yielding processes for the manufacture of bispecific antibodies, Christel Veyssier, Principal Scientist, F-star Biotechnology
- Cyclotides: Robust microproteins for the generation of bi- and tri-specific anti-cancer agents - Bill Eldridge, Chief Scientific Officer, Cyclogenix
13.00 – 14.00
Networking Lunch
14.00 – 15.00
Drop-in-Clinic Sessions Continue
- Meet Lonza specialists at pre-booked 1-on-1 sessions
- Parallel session featuring presentations from industry
Speakers include:
- Antigen and Antibody Expression within Biologics Drug Discovery at CMAL - Stuart Haynes, Principal Scientist, The Cancer Research UK Alliance Laboratory (CMAL)
15.00 – 15.30
Networking Tea and Coffee and Event Closes
Babraham Research Campus
Cambridge, Cambridgeshire CB22 3AT
United Kingdom